Marksans Pharma Ltd.

08th August, 2015

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block –G
Bandra – Kurla Complex,
Bandra (E), Mumbai – 400051.

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoi Towers,
Dalal Street,
Mumbai 400 001

Sub: News Release

Dear Sir,

Enclosed herewith kindly find a News Release dated 08th August, 2015 of the Company.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed as above

Marksans Pharma Ltd.

NEWS RELEASE
8th August 2015, Mumbai - India

Performance Highlights.

Marksans Consolidated PAT up by 23.55% in quarter I, FY 2015-16, as compared to last year same quarter.

- Consolidated Revenue grew to Rs 2101.59 * Mn in Q1 FY 2015-16.
- EBITDA grew by 22.45% to Rs 524.06 Mn for the quarter. EBITDA margin grew to 24.67% from 21.14% for the quarter.
- Consolidated Net Profit after Tax was Rs 314.69 Mn for the Q1 FY 2015-16.
- Post – Tax profits up by 23.55% same quarter in the previous year.

Business Highlights

- US & North America Formulation business grew by 21.77% to Rs. 431.63 Mn from Rs. 354.47 Mn during Q1 FY 2015-16.
- Europe, UK Formulation business grew to Rs.1332.40 Mn during Q1 FY 2015-16.
- Australia & NZ business grew to Rs. 191.55 Mn during Q1 FY 2015-16.
- Company achieved revenue of Rs.146.01Mn from Rest of World(Asia,Africa & CIS) Formulation business during Q1 FY 2015-16.

Revenue Figures - Consolidated

	INR in million	
	Q1 FY 2015-16	**Q1 FY 2014-15**
US & North America – Formulations	431.63	354.47
Europe, UK-Formulations	1332.40	1323.41
Australia & NZ - Formulations	191.55	188.79
Rest of World(ROW) - Africa, Asia & CIS-Formulations	146.01	157.28
Consolidated Revenue from operations	2101.59	2023.95

* Consolidated Revenue does not include revenue of Time-Cap Laboratories Inc.

Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com

Time-Cap Laboratories Inc. Acquisition

Marksans Pharma Ltd.

During the quarter, Marksans Pharma Limited has, through its wholly owned subsidiary, Marksans Pharma Inc., acquired 100% of the outstanding shares of Time-Cap Laboratories, Inc., a New York corporation having its principal office at 7 Michael Avenue, Farmingdale, New York.

Time-Cap was founded in 1979 and is a leading manufacturer and marketer of solid dose generic pharmaceuticals, including private label over-the-counter ("OTC") medications, generic prescription drugs ("Rx"), and nutritional supplements. Time-Cap manufactures over 50 unique products from its facility in Farmingdale, New York, including tablets, caplets, capsules and pellets. Time-Cap's average annual revenue over the last four years is in excess of USD 30 million per annum, and it achieved an average annual adjusted EBITDA of approximately USD 4 million. The company presently has no debt.

Key Highlights

- Time-Cap has a US FDA-approved manufacturing facility in Farmingdale, New York.
- It has an experienced research and development team which over the years has optimized its production processes and introduced a number of new products.
- Time-Cap has developed differentiating manufacturing expertise, resulting in a key competitive advantage in the market place for extended and delayed-release products, and coating services.
- The company has substantial growth opportunities with a robust new product line in the pipeline. Its capabilities with respect to extended-release products offer opportunities to pursue ANDAs for high margin products.
- Time-Cap has an expert management team comprised of industry pioneers with deep expertise, as well as a loyal and technically sophisticated employee base.

With its acquisition of Time-Cap, Marksans is strategically increasing its presence in the US market, which is the largest pharmaceutical market in the world. This transaction will be EPS accretive.

The Consolidated financial statement does not include financial statement of Time-Cap Laboratories Inc.

About Marksans Pharma Limited

Marksans Pharma Limited(www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MKRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited
11th Floor, "GRANDEUR", Opp. Gundecha Symphony,
Veera desia Extension Road,Oshiwara, Andheri – West, Mumbai – 400 053, India
Tel:- +91 22 4001 2000, Fax:- +91 22 4001 2011.